Palate destruction by aspergillus

New England Journal of Medicine

Volumn 337, Issue 4, 1997, Pages 241-

  Schwartz, Stefan ^a   Thiel, Eckhard ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYTARABINE; IDARUBICIN; ITRACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; ASPERGILLOSIS; CASE REPORT; CLEFT PALATE; DRUG MEGADOSE; HARD PALATE; HUMAN; MALE; PRIORITY JOURNAL; PROSTHESIS;

EID: 1842326764     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199707243370405     Document Type: Article

References (122)

1. Scher H, Bosl G, Geller N, Cirrincione C, Whitmore W, Golbey R. Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. Urology 1983;21:559-61.
2. Bosl GJ, Vogelzang NJ, Goldman A, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981;2:970-3.
3. Feuer EJ, Frey CM, Brawley OW, et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994;12:368-77.
4. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF Jr. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-82.
5. Bosl GJ, Bajorin D, Sheinfeld J, Motzer R. Cancer of the testis. In: DeVita VT, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: J.B. Lippincott, 1997:1397-425.
6. Daniels JL Jr, Stutzman RE, McLeod DG. A comparison of testicular tumors in black and white patients. J Urol 1981;125:341-2.
7. Forman D, Oliver RT, Brett AR, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 1992;65:255-62.
8. Nichols CR, Heerema NA, Palmer C, Loehrer PJ, Williams SD, Einhorn LH. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 1987;5:1290-4.
9. Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol 1995;13:1391-7.
10. Bernardi D, Salvioni R, Vaccher E, et al. Testicular germ cell tumors and human immunodeficiency virus infection: a report of 26 cases. J Clin Oncol 1995;13:2705-11.
11. Coscrove MD, Benton B, Henderson BE. Male genitourinary abnormalities and maternal diethylstilbestrol. J Urol 1977;117:220-2.
12. Mattingly RF, Stafl A. Cancer risk in diethylstilbestrol-exposed offspring. Am J Obstet Gynecol 1976;126:543-8.
13. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112:232-46.
14. Giwercman A, Muller J, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes from 399 men who died suddenly and unexpectedly. J Urol 1991;145:77-80.
15. Jacobsen GK, Henriksen OB, von der Maase HV. Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer 1981;47:2660-2.
16. Daugaard G, von der Masse H, Olsen J, Rorth M, Skakkebaek NE. Carcinoma-in-situ testis in patients with assumed extragonadal germ-cell tumors. Lancet 1987;2:528-30.
17. Skakkebaek NE, Berthelsen JG, Muller J. Carcinoma-in-situ of the undescended testis. Urol Clin North Am 1982;8:377-85.
18. Mostofi FK, Sesterhenn IA. Revised international classification of testicular tumours. In: Jones WG, Harnden P, Appleyard I, eds. Germ cell tumours III. Vol. 91 of Advances in the biosciences. Oxford, England: Pergamon Press, 1994:153-8.
19. Cockburn AG, Vugrin D, Batata M, Hajdu S, Whitmore WF. Poorly differentiated (anaplastic) seminoma of the testis. Cancer 1984;53:1991-4.
20. Muller J, Skakkebaek NE, Parkinson MC. The spermatocytic seminoma: views on pathogenesis. Int J Androl 1987;10:147-56.
21. Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985;56:860-3.
22. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990;322:1425-9.
23. Chaganti RSK, Rodriguez E, Bosl GJ. Cytogenetics of male germ-cell tumors. Urol Clin North Am 1993;20:55-66.
24. de Jong B, Oosterhuis JW, Castedo SM, Vos A, te Meerman G. Pathogenesis of adult testicular germ cell tumors: a cytogenetic model. Cancer Genet Cytogenet 1990;48:143-67.
25. Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, Chaganti RS. Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 1992;52:2285-91.
26. Vos A, Oosterhuis JW, de Jong B, Buist J, Koops SH. Cytogenetics of carcinoma in situ of the testis. Cancer Genet Cytogenet 1990;46:75-81.
27. Rodriguez E, Houldsworth J, Reuter VE, et al. Molecular cytogenctic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer 1993;8:230-6.
28. Chaganti RS, Ladanyi M, Samaniego F, et al. Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes Cancer 1989;1:83-7.
29. Bosl GJ, Ilson DH, Rodriguez E, Motzer RJ, Reuter VE, Chaganti RSK. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994;86:349-55.
30. Murty VVVS, Bosl GJ, Houldsworth J, et al. Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene 1994;9:2245-51.
31. Murty VV, Houldsworth J, Baldwin S, et al. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. Proc Natl Acad Sci U S A 1992;89:11006-10.
32. Battifora H, Sheibani K, Tubbs RR, Kopinski MI, Sun TT. Antikeratin antibodies in tumor diagnosis: distinction between seminoma and embryonal carcinoma. Cancer 1984;54:843-8.
33. Manivel JC, Jessurun J, Wick MR, Dehner LP. Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms. Am J Surg Pathol 1987;11:21-9.
34. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315-20.
35. Ray B, Hajdu SI, Whitmore WF Jr. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 1974;33: 340-8.
36. Lien HH, Stenwig AE, Ous S, Fossa SD. Influence of different criteria for abnormal lymph node size on reliability of computed tomography in patients with non-seminomatous testicular cancer. Acta Radiol 1986;27: 199-203.
37. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120-6.
38. Bosl GJ, Gluckman R, Geller NL, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986;4: 1493-9.
39. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990;50:5904-10.
40. Thomas GM, Rider WD, Dembo AJ, et al. Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 1982;8:165-74.
41. Hamilton C, Horwich A, Easton D, Peckham MJ. Radiotherapy for stage I seminoma testis: results of treatment and complications. Radiother Oncol 1986;6:115-20.
42. Gregory C, Peckham MJ. Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 1986;6:285-92.
43. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: results of the national practice in seminoma of the testis. Int J Radiat Oncol Biol Phys 1981;7:1413-7.
44. Zagars GK, Babaian RJ. The role of radiation in stage II testicular seminoma. Int J Radiat Oncol Biol Phys 1987;13:163-70.
45. Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383-8.
46. Horwich A. Surveillance for stage I seminoma of the testis. In: Horwich A, ed. Testicular cancer: investigation and management. London: Chapman & Hall, 1991:109-16.
47. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255-62.
48. Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986;4:1031-6.
49. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study: Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990;8:509-18.
50. Dunphy CH, Ayala AG, Swanson DA, Ro JV, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis: a clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 1988;62:1202-6.
51. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995;13:1188-94.
52. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995;154:1045-9.
53. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762-8.
54. Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am 1991;18:561-73.
55. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Br J Urol 1993;71:326-35.
56. Idem. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237-43.
57. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982; 127:685-8.
58. Cullen M, Stenning S, Parkinson M, et al. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumours of the testis (NSGCTT): an MRC(UK) study report. Proc Am Soc Clin Oncol 1995;14:244. abstract.
59. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441-8.
60. Oliver RTD, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148: 1453-6.
61. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111-4.
62. Saxman SB, Nichols CR, Foster RS, Messemer JE, Donohue JP, Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 1996;155:587-9.
63. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393-6.
64. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433-8.
65. Pizzocaro G, Piva L, Salvioni R, Pasi M, Pilotti S, Monfardim S. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of the testis: in which cases is it necessary? Eur Urol 1984;10(3):151-8.
66. Skinner DG, Scardino PT. Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective. J Urol 1980;123:378-82.
67. Vugrin D, Whitmore W, Cvitkovic E, Grabstald H, Sogani P, Golbey RB. Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer. Cancer 1981;48:233-7.
68. Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 1991;146:1295-8.
69. Vugrin D, Whitmore WF Jr, Herr HW, Sogani P, Golbey RB. VAB-6 combination chemotherapy in resected stage II-B testis cancer. Cancer 1983;51:5-8.
70. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995;13:2700-4.
71. Willan BD, McGowan DG. Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 1985;11:1769-75.
72. Ellerbroek NA, Tran LM, Selch MT, Taylor JM, Parker RG. Testicular seminoma: a study of 103 cases treated at UCLA. Am J Clin Oncol 1988; 11:93-9.
73. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275-80.
74. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981; 305:727-31.
75. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
76. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95:288-92.
77. Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43:3403-7.
78. Birch R, Williams S, Cone A, et al. Prognostic factors for tavorable outcome in disseminated germ cell tumors. J Clin Oncol 1986;4:400-7.
79. Mead GM. International Consensus prognostic classification for metastatic germ cell tumors treated with platinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 1995;14:235. abstract.
80. Bosl GJ. Management of metastatic germ cell tumors: toxicity reduction and the use of bleomycin. In: Horwich A, ed. Testicular cancer: investigation and management. 2nd ed. London: Chapman & Hall Medical, 1996:251-7.
81. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988;6:1231-8.
82. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7: 387-91.
83. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-6.
84. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598-606.
85. Horwich A, Sleijfer D, Fossa S, et al. A trial of carboplatin based combination chemotherapy in good prognosis metastatic testicular nonseminoma. Proc Am Soc Clin Oncol 1994;13:230. abstract.
86. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
87. Nichols CR, Loehrer PJ, Einhorn LH, Propert K, Vogelzang NJ. Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors: an intergroup trial. Proc Am Soc Clin Oncol 1995;14:239. abstract.
88. de Wit R, Stoter G, Kaye SB, et al. The importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-43.
89. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-9.
90. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84: 1703-9.
91. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol (in press).
92. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
93. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294-9.
94. Panicek DM, Toner GC, Heelan RT, Bosl GJ. Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy. Radiology 1990;175: 499-502.
95. Lorigan JG, Eftekhari F, David CL, Shirkhoda A. The growing teratoma syndrome: an unusual manifestation of treated, nonseminomatous germ cell tumors of the testis. AJR Am J Roentgenol 1988;151:325-9.
96. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176-9.
97. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569-73.
98. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR Am J Roentgenol 1985;145:743-6.
99. Little JS Jr, Foster RS, Ulbright TM, Donohue JP. Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. J Urol 1994;152:1144-9.
100. Miller K, Loehrer P, Einhorn L. Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma: long term follow-up. Proc Am Soc Clin Oncol 1996;15:240. abstract.
101. Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1992;19: Suppl 12:8-11.
102. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-41.
103. Broun ER, Nichols CR, Kneebonc P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992;117:124-8.
104. Linkesch W, Greinix HT, Hocker P, Krainer M, Wagner A. Longterm follow up of phase I/II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 1993;12:232. abstract.
105. Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991;67:1305-10.
106. Motzer R, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996;14:1098-105.
107. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-83.
108. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-4.
109. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
110. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985;56:2765-70.
111. Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990;66:2476-81.
112. Lange PH, Narayan P, Fraley EE. Fertility issues following therapy for testicular cancer. Semin Urol 1984;2:264-74.
113. Stephenson WT, Poirer SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995;13:2278-80.
114. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24.
115. Jacobsen GK, Mellemgaard A, Engelholm SA, Moller H. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur J Cancer 1993;29A:664-8.
116. Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60-2.
117. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993;85:36-40.
118. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991;338:359-63.
119. Tonor GC, Bosl GJ. Sarcoidosis, "sarcoid-like lymphadenopathy," and testicular germ cell tumors. Am J Med 1990;89:651-6.
120. Hainsworth JD, Greco FA. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site. Semin Oncol 1993;20:279-86.
121. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992;10:912-22.
122. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RSK. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995;13:274-82.